Atezolizumab for Previously Treated Non-Small Cell Lung Cancer: Julien Mazières, MD, PhD

For patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC), effective treatment options with minimal toxicity remain limited. In this interview with i3 Health, Julien Mazières, MD, PhD, Professor of Respiratory Medicine at Toulouse University Hospital, discusses his collaborative research finding that atezolizumab increases long-term overall survival compared with docetaxel, regardless of histology, subsequent immunotherapy, and programmed death ligand...
Continue reading

Atezolizumab Improves Overall Survival in Non-Small Cell Lung Cancer

In patients with previously treated non-small cell lung cancer (NSCLC), atezolizumab increases overall survival compared with docetaxel, regardless of programmed death ligand 1 (PD-L1) status, histology, and subsequent immunotherapy, according to a new study published in the Journal of Thoracic Oncology. "In clinical trials conducted with immunotherapy, the benefit to patients is usually sustained over time," write the investigators, led by first author Julien Mazieres, MD, PhD, Professor of Res...
Continue reading

Atezolizumab Combo Effective in EGFR-Mutated Non-Small Cell Lung Cancer

The addition of atezolizumab to bevacizumab/carboplatin/paclitaxel (BCP) significantly prolongs overall survival in patients with non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, according to results of a final efficacy analysis presented this week at the European Medical Society for Oncology (ESMO) Virtual Congress 2020. "Atezolizumab inhibits programmed death-ligand 1 (PD-L1) to restore anti-cancer immunity; bevacizumab may enhance atezoli...
Continue reading

FDA Alert: Atezolizumab/Paclitaxel Ineffective for Triple-Negative Breast Cancer

The FDA has issued an alert regarding the combination of atezolizumab (Tecentriq®, Genentech) and paclitaxel for the treatment of patients with previously untreated, inoperable locally advanced or metastatic triple-negative breast cancer (TNBC). In addition to being ineffective, atezolizumab/paclitaxel can negatively impact overall survival. While atezolizumab/paclitaxel is not approved for the treatment of breast cancer, atezolizumab in combination with paclitaxel protein-bound particles, also ...
Continue reading

Atezolizumab Triplet Therapy for BRAF V600-Mutant Melanoma: Paolo A. Ascierto, MD

Recently, the FDA approved a new indication for atezolizumab (Tecentriq®, Genentech) in combination with vemurafenib (Zelboraf®, Genentech and Daiichi-Sankyo) and cobimetinib (Cotellic®, Genentech) for the treatment of BRAF V600-mutant advanced melanoma. In this interview with i3 Health, Paolo A. Ascierto, MD, principal investigator of the IMspire150 trial, on which the approval was based, discusses the approval's significance and the most promising research developments in the treatment of BRAF...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.